OS of group 1 patients as reclassified.

(A) OS of the group 1 patients reclassified into risk groups using bcl-2 and GC phenotype in combination with IPI. Kaplan-Meier analysis demonstrating that the sequential addition of bcl-2 and GC status into the IPI allows effective risk stratification of 85% of patients. Patients with IPI high or IPI intermediate with bcl-2 expression have a poor outcome and patients with IPI low or IPI intermediate without bcl-2 but with GC phenotype have a favorable prognosis. Twenty-four patients do not fit either category and retain an undetermined outcome. (B) OS of the group 1 patients assigned with a “score” of 1 each for an IPI more than 2, bcl-2 in more than 50% of tumor cells and the lack of a GC phenotype. Kaplan-Meier analysis demonstrating that cellular factors can potentially be added to the IPI to improve risk stratification in nodal DLBCL. Patients scoring 0 or 1 have a more than 60% chance of survival at 5 years compared to a less than 35% chance with a score of 2 or 3.